Alumis (ALMS) shares climbed nearly 150% on Tuesday after the autoimmune disease drug developer said its lead candidate, envudeucitinib, reached the main goals in two Phase 3 trials for a skin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results